NTET answer key 2025: Last date to submit objections today, details here
NTET 2025 was conducted on July 17, 2025.
'Challenges made by the candidates will be verified by the panel of subject experts. If found correct, the answer key will be revised accordingly. Based on the revised Final Answer Key, the result will be prepared and declared. No individual candidate will be informed about the acceptance/non-acceptance of his/her challenge. The key finalized by the Experts after the challenge will be final,' reads the notification.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
15 minutes ago
- Time of India
Hypertension no bar: Insurance agency asked to pay 2L claim
Ghaziabad: Ruling that medical claims cannot be rejected on the grounds that a person has hypertension, the district consumer disputes redressal commission (DCDRC) has directed an insurance firm to pay Rs 2.1 lakh to a Ghaziabad man whose request was denied. DCDRC president Praveen Kumar Jain and members RP Singh and Shailja Sachan also ordered the insurer – Religare Health Insurance Company – to pay Kapil Anand Rs 5,000 as compensation for litigation costs and denial of the claim filed in 2019. The payment must be made within 45 days, and failure to comply will attract 6% simple interest on the outstanding amount. In a plea filed with the consumer commission, Anand said he'd bought the Rs 5-lakh policy from Religare after paying a premium of Rs 17,150 on March 3, 2019. You Can Also Check: Noida AQI | Weather in Noida | Bank Holidays in Noida | Public Holidays in Noida In Oct that year, he felt "discomfort" in his chest and was admitted to Yashoda Hospital. "… doctors diagnosed me with a blockage in the heart and I underwent the medical procedure of stenting in the heart," he said. The third-party administrator, he said, refused to pay his hospital bill of Rs 2,16,482 lakh, forcing him to pay it on his own. Religare's counsel argued before the commission that Anand did not disclose his history of hypertension at the time of buying the policy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She Was Everyone's Dream Girl In 90's, This Is Her Now The Latest Article Undo "The discharge slip, consultation papers, and past history of the patient mentioned that he suffered from hypertension for the last two years and he did not disclose this at the time of purchasing the policy," the counsel said, adding that any condition linked to hypertension cannot be honoured for a claim. The commission in its July 26 order cited two previous judgments by NCDRC-New Delhi to rule in favour of Anand. In the 2013 Ravindra Bindra vs National Insurance Company case, the Delhi commission had ruled that hypertension history could not be grounds for rejecting heart treatment claims, it said. In another 2013 case (Satish Chandra Madan vs Bajaj Alliance), NCDRC rejected the argument that hypertension was a chronic disease. "In the case Satish Chandra Madan Vs Bajal Alliance General Insurance Company, National Consumer Disputes Redressal Commission held that the petitioner was a patient of hypertension before securing the insurance policy. Hypertension is a common ailment that can be treated through medicines and it is not necessary that hypertension was linked to heart attack. Hypertension is a lifestyle disease and by rejecting the claim, insurance company is guilty of deficiency in service," the Ghaziabad commission said in its order. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
NDTV
an hour ago
- NDTV
Centre Cuts Prices Of 35 Essential Medicines
In a move to make medicines more affordable for patients, the National Pharmaceutical Pricing Authority (NPPA) has reduced the retail prices of 35 essential drugs sold by leading pharmaceutical companies. The formulations, which will now cost less, span a wide range of medicines including anti-inflammatory, cardiovascular, antibiotic, anti-diabetic and psychiatric medicines. The Ministry of Chemicals and Fertilisers notified the order based on price regulation by the NPPA. The price reductions, which apply across drugs, are expected to bring relief to consumers, particularly those managing chronic conditions. The key formulations covered by the price control order include fixed-dose combinations of Aceclofenac, Paracetamol and Trypsin Chymotrypsin, Amoxycillin and Potassium Clavulanate, Atorvastatin combinations and newer oral anti-diabetic combinations like Empagliflozin, Sitagliptin, and Metformin. The price of one Aceclofenac-Paracetamol-Trypsin Chymotrypsin tablet manufactured by Akums Drugs & Pharmaceuticals and marketed by Dr Reddy's Laboratories has now been fixed at Rs 13, while the same formulation marketed by Cadila Pharmaceuticals is now priced at Rs 15.01. Similarly, a tablet containing Atorvastatin 40 mg and Clopidogrel 75 mg, widely used for cardiovascular conditions, is priced at Rs 25.61. Oral suspensions for paediatric use - Cefixime and Paracetamol combinations - have also been included, along with critical medications like Cholecalciferol drops for Vitamin D supplementation and Diclofenac Injection, which has been priced at Rs 31.77 per ml. The official order states that retailers and dealers must display these updated price lists prominently in their premises. Failure to comply with the notified prices may attract penal provisions under the DPCO, 2013, and the Essential Commodities Act, 1955, including recovery of overcharged amounts with interest. The NPPA clarified that the prices fixed were exclusive of Goods and Services Tax (GST), which may be added, if applicable. Manufacturers are required to comply with all statutory requirements, issue updated price lists in Form V through the Integrated Pharmaceutical Database Management System and submit the information to the NPPA and state drug controllers. Any prior price orders issued for the specified formulations and manufacturers stand superseded by this latest notification. The NPPA, which functions under the Ministry of Chemicals and Fertilisers, is the drug price regulator in India, responsible for fixing and revising prices of pharmaceutical products and monitoring the prices of both controlled and decontrolled drugs.
Time of India
4 hours ago
- Time of India
Manipal Hospitals seeks CCI nod to acquire Sahyadri Hospitals for about Rs 6,400 cr
New Delhi: Healthcare major Manipal Hospitals has sought approval from the fair trade regulator CCI to acquire Pune-based Sahyadri Hospitals from global investor Ontario Teachers' Pension Plan Board in a deal pegged at around Rs 6,400 crore. The companies did not share the deal size, but industry sources estimate the transaction to be in the range of Rs 6,200-6,400 crore. "The proposed transaction envisages the acquisition of up to 100 per cent shareholding by the acquirer (Manipal Hospitals Pvt Ltd) in the target (Sahyadri Hospitals Pvt Ltd) in multiple tranches," according to a notice filed with the Competition Commission of India (CCI). Manipal Hospitals and Sahyadri Hospitals said the "proposed transaction does not have any impact on any relevant market in India, let alone any appreciable adverse effect on competition (AAEC), and therefore, the definition of the relevant product and geographic market may ultimately be left open. In any event, in order to aid and assist the CCI in its assessment". Last month, Manipal Hospitals announced that it had inked definitive agreements with Ontario Teachers' for the acquisition. The Bengaluru-based healthcare major said the acquisition of Sahyadri Hospitals will bring Manipal's total bed count to about 12,000, making it one of India's largest hospital networks. The acquisition will add 11 hospitals to Manipal's network across Pune, Nashik, Ahilya Nagar and Karad, increasing its total number of hospitals to 49, it added. Through this acquisition, Manipal said it will expand its presence in western India, in line with its strategy to augment its pan-India footprint. "With the strong partnership of our valued stakeholders like Temasek and our other investors, we are excited to grow our operations and bring Manipal's trusted brand of quality healthcare to many more patients," Manipal Health Enterprises MD and CEO Dilip Jose said. Manipal Education and Medical Group (MEMG) Chairman Ranjan Pai said the acquisition will strengthen Manipal's presence in western India. "With this expansion, Manipal Hospitals will have a network of approximately 12,000 beds nationwide, solidifying our position as one of the largest hospital chains in India," he added. Manipal Hospitals is backed by Temasek, a global investment company, headquartered in Singapore, with a net portfolio value of around USD 324 billion as of March 31, 2025. A global investor with net assets of USD 266.3 billion as of December 31, 2024, Ontario Teachers' Pension Plan Board (Ontario Teachers') acquired a majority stake in Sahyadri in 2022. The Pune-based hospital chain is now one of Maharashtra's largest, with 11 hospitals and over 1,400 beds.
